Exelixis | EXEL - Sales Revenues



Exelixis reported $568.3M in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
Acadia Pharmaceuticals USD 264.6M 20.28M Jun/2025
Agios Pharmaceuticals USD 12.45M 3.75M Jun/2025
Amgen USD 9.18B 1.03B Jun/2025
AstraZeneca USD 14.46B 867M Jun/2025
Bayer EUR 10.74B 3B Jun/2025
BioMarin Pharmaceutical USD 825M 80M Jun/2025
Bristol-Myers Squibb USD 12.27B 1.07B Jun/2025
Cytokinetics USD 66.76M 65.16M Jun/2025
Eisai JPY 202.65B 14.41B Jun/2025
Eli Lilly USD 15.56B 2.83B Jun/2025
Exelixis USD 568.3M 12.9M Jun/2025
Genmab DKK 5.86B 580M Jun/2025
Glaxosmithkline GBP 7.99B 131M Jun/2025
Incyte USD 1.06B 10M Jun/2025
Ionis Pharmaceuticals USD 452M 320M Jun/2025
MacroGenics USD 22.24M 2.89M Jun/2025
Merck USD 15.81B 280M Jun/2025
Moderna USD 142M 34M Jun/2025
Neurocrine Biosciences USD 687.5M 114.9M Jun/2025
Novartis USD 14.05B 821M Jun/2025
Pfizer USD 14.7B 980M Jun/2025
Sanofi EUR 10.74B 529.51M Jun/2025
Takeda JPY 1.11T 60B Jun/2025
Ultragenyx Pharmaceutical USD 166.5M 27.21M Jun/2025
Xencor USD 43.61M 10.88M Jun/2025